Search clinical trials for: 89Zr-TLX250 (89Zirconium-TLX250) PET/CT

Total 716 results

Telix Pharmaceuticals (Innovations) Pty Limited

Completed

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (89ZR-TLX250)

Clear Cell Renal Cell Carcinoma

United Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
Telix International Pty Ltd

Completed

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (ZIRDAC-JP)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Japan
Telix International Pty Ltd
Grand Pharmaceutical (China) Co., Ltd.

Completed

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma (ZIRDOSE-CP)

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell Carcinoma

China
Institut Cancerologie de l'Ouest
ATONCO

Completed

Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC) (PERTINENCE)

Bladder Cancer

France
Institut Cancerologie de l'Ouest
Telix Pharmaceutical; SIRIC ILIAD

Recruiting

Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients (OPALESCENCE)

Triple Negative Breast Cancer

France
Telix Pharmaceuticals (Innovations) Pty Limited
Merck KGaA, Darmstadt, Germany

Recruiting

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Advanced Solid Tumor | Solid Tumor, Adult | Advanced Renal Cell Carcinoma

Australia
Telix Pharmaceuticals (Innovations) Pty Limited

Available

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Clear Cell Renal Cell Carcinoma

United States
Telix International Pty Ltd

Recruiting

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Soft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditions

United States
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited

Not yet recruiting

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Stage II Renal Cell Cancer

United States
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC

Unknown

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Non Small Cell Lung Cancer

Netherlands
Memorial Sloan Kettering Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Breast Cancer Metastases | HER2 Positive Breast

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University

Completed

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Glioblastoma

United States
Olivia Newton-John Cancer Research Institute
Austin Health; Merck Healthcare KGaA

Terminated

Bioimaging Study of 89Zr-M7824 in NSCLC

Non-Small Cell Lung Cancer

Australia
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
University Medical Center Groningen

Active, not recruiting

MPDL3280A-imaging-IST-UMCG

Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

Netherlands
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY008 PET Imaging in Patients

Multiple Myeloma

China
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors

Solid Tumor, Adult

China
Wuxi No. 4 People's Hospital

Unknown

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Solid Tumor, Adult

China
South Metropolitan Health Service
Telix Pharmaceuticals (Innovations) Pty Limited

Completed

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients (ZiPUP)

Urothelial Carcinoma

Australia
Radboud University Medical Center
ABX CRO; Telix International Pty Ltd

Completed

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Clear Cell Renal Carcinoma

Netherlands
GlaxoSmithKline

Terminated

Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

Amyloidosis

Sweden
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

Prostate Cancer

United States
Robert Flavell, MD, PhD

Suspended

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Rheumatoid Arthritis

United States
University of Saskatchewan

Recruiting

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Colorectal Cancer | Lung Cancer

Canada
University of Alabama at Birmingham

Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Breast Cancer

United States
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY009 PET Imaging in Patients

Cancer

China
Sinotau Pharmaceutical Group

Not yet recruiting

Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors

Solid Tumor
ImaginAb, Inc.

Recruiting

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT)

Melanoma | Renal Cell Carcinoma | Non Small Cell Lung Cancer | Merkel Cell Carcinoma, Unspecified

United States, Australia, Belgium, Netherlands, Switzerland, United Kingdom
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult

China
Huashan Hospital

Unknown

The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma

Glioma

China
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands
GlaxoSmithKline
PRA Health Sciences for clinical study conduct.

Completed

A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

Drug-Related Side Effects and Adverse Reactions

Netherlands
ImaginAb, Inc.

Completed

Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy

Prostate Cancer

United States
ImaginAb, Inc.

Completed

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer (IAB2M)

Metastatic Prostate Cancer

United States
ImaginAb, Inc.

Withdrawn

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer

Prostate Cancer

United States
Radboud University Medical Center
Merck KGaA, Darmstadt, Germany

Completed

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) (PINNACLE)

Non Small Cell Lung Cancer

Netherlands
Université de Sherbrooke
Eli Lilly and Company; Chorus Wellness Inc.; AL-S Pharma AG

Recruiting

Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Canada
University Medical Center Groningen
Genentech, Inc.; Amsterdam UMC, location VUmc

Completed

89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients (MMOT)

Digestive System Diseases | Ovarian Diseases | Adnexal Diseases | Digestive System Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Pancreatic Diseases

Netherlands
The First Affiliated Hospital of Soochow University
MITRO Biotech Co., Ltd.

Unknown

89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
University Medical Center Groningen

Completed

89Zr-AMG211 PET Imaging Study

Advanced Gastrointestinal Cancer

Netherlands
University Medical Center Groningen

Completed

Pembrolizumab-PET Imaging

Melanoma | Non-small Cell Lung Cancer

Netherlands
Radboud University Medical Center
ImaginAb, Inc.

Recruiting

CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

PET Imaging | Lymphopenia Due to COVID-19 | T-cell

Netherlands
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands
Biogen

Not yet recruiting

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Healthy Volunteer
Memorial Sloan Kettering Cancer Center

Active, not recruiting

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

DLBCL | Large B-cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
BioNTech SE

Active, not recruiting

Study of a New Technique for Imaging Pancreatic Cancer

Pancreatic Cancer | Tumors That Express CA19-9

United States
Amsterdam UMC, location VUmc
Foundation for the National Institutes of Health

Not yet recruiting

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer (iRelate)

NSCLC

Netherlands
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Inflammatory Breast Carcinoma

United States
Karolinska University Hospital

Recruiting

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer (MIMIR-mTNBC)

Metastatic Triple-Negative Breast Carcinoma

Sweden
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States

Search clinical trials for: 89Zr-TLX250 (89Zirconium-TLX250) PET/CT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations